The advancement follows the receiving of $40m by FibroGen from its partner Astellas in the fourth quarter of 2010 under Astellas’ license to rights for the European Union and certain other territories.
FibroGen CEO Thomas Neff said they are pleased to report progress in the clinical development program for FG-4592 for the treatment of anemia in CKD patients on dialysis and not on dialysis.
"We continue to see signs of potential therapeutic advantages of FG-4592 compared to ESAs, such as clinical evidence that FG-4592 is potentially superior by certain efficacy measures such as median time to achieve hemoglobin correction," Neff said.